Mirati Therapeutics (NASDAQ:MRTX) will collaborate with Novartis (NYSE:NVS) on a clinical trial to evaluate the combination of MRTX849, a KRAS G12C inhibitor, and the latter’s TNO155, a SHP2 inhibitor, in patients with solid tumors that harbor KRAS G12C mutations.
Under the terms of the agreement, MRTX will sponsor the study while NVS will provide product. Both companies will manage and share the costs of clinical development.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.